Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : MAXY - Maxygen, Inc. -- Ignore unavailable to you. Want to Upgrade?

To: nigel bates who wrote (139)	5/22/2003 1:41:07 PM
From: Madharry	Respond to of 262

Nice pR release. I wish they released a little more info about the payments.

To: nigel bates who wrote (139)	5/22/2003 9:16:17 PM
From: Madharry	Respond to of 262

I listened to most of the conference call- What I came away with- 1. Goldman Sachs and JP Morgan had people asking questions. 2. The company hardly disclosed any additional information - other than Roche was paying an upfront fee and had committed to funding R&D for a 2 year period -preusmably long enough to bring to NDA filings. 3. Roche had enough of a look see to believe that products could be developed that were better than anything existing today. Based on the above I am quite happy to be a long term shareholder. The company still has a healthy cash balance and now gets to use someone elses money for a significant research endeavor.